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Causes and Outcomes of Spontaneous Pneumothoraces in
Solid Tumor Cancer Patients: An Update for the
Medical Oncologist
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Purpose: Defined as lung collapse in the absence of a recent
invasive thoracic procedure, a spontaneous pneumothorax can be a
catastrophic event, leading to abrupt shortness of breath, chest pain,
hypotension, and occasionally death. A dearth of present day infor-
mation on this entity in solid tumor cancer patients prompted this
single-institution retrospective study on current causes and out-
comes.
Methods: All patients with diagnoses of “spontaneous pneumotho-
rax” and “cancer” between 1990 and 2004 had their records re-
trieved and reviewed. Among 546 patients with a diagnosis of
spontaneous pneumothorax, only 25 (5%) met predefined inclusion
criteria that included an antecedent diagnosis of an invasive solid
tumor malignancy. Lung (n  5) and bladder cancer (n  4) were
the most common malignancies; eight patients had received radia-
tion and one had received carmustine. Of note, 78% were smokers,
13 had chronic obstructive pulmonary disease, and 12 had no known
active cancer at the time of the pneumothorax.
Results: Pneumothorax management was associated with great
morbidity, including hospitalization in 24 patients and chest tube
placement and/or surgery in most patients. Median survival for the
group as a whole was 31 months, but patients with known active
cancer tended to do poorly, with only a 3-month median survival.
Conclusion: A spontaneous pneumothorax is rare, and patients with
known active cancer tend to do poorly. However, even patients with
no known active cancer are at risk, perhaps in part from smoking.
The fact that patients with no known active cancer can live for years
after this event suggests that the pneumothorax should not be
assumed to be related to cancer recurrence, that cancer restaging is
not always mandatory, and that there is justification for managing
the pneumothorax in this subgroup aggressively.
Key Words: Spontaneous pneumothorax, Lung cancer, Bladder
cancer, Survival.
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A spontaneous pneumothorax can be a catastrophic event.Defined as lung collapse in the absence of a recent
invasive thoracic procedure, a spontaneous pneumothorax
can lead to abrupt shortness of breath, chest pain, hypoten-
sion, and occasionally death. Although it can resolve with
conservative management, patients typically undergo hospi-
talization and often require chest tube placement. Previous
studies suggest that fewer than 1% of cancer patients suffer
from a spontaneous pneumothorax, but when it does occur, it
can bring with it tremendous morbidity.1,2
How does a spontaneous pneumothorax occur in cancer
patients? The medical literature provides three plausible ex-
planations3: (1) a bronchopleural fistula develops within ne-
crotic tumor, establishes a communication between the bron-
chus and pleura, and thereby results in a spontaneous
pneumothorax; (2) a tumor-induced rupture of a subpleural
bleb leads to an imbalance of intrathoracic pressures and
results in a spontaneous pneumothorax; and (3) direct pleural
invasion by the tumor again causes an imbalance of intratho-
racic pressures and once again results in a spontaneous
pneumothorax.
Such putative mechanisms add to our understanding of
this entity but do not address the clinical circumstances and
implications underlying a diagnosis of a spontaneous pneu-
mothorax. Multiple case reports and small case series are
invaluable in this regard. Such reports tell us that spontaneous
pneumothoraces are more commonly observed in patients
with lung cancer and sarcoma but can also occur in patients
with gynecologic malignancies, rectal cancer, renal cell car-
cinoma, testicular cancer, and lymphoma.1,2–7 A spontaneous
pneumothorax often suggests cancer recurrence or progres-
sion and heralds demise within only a few months.1,4 Prior
treatment, such as radiation or carmustine-based chemother-
apy, is often associated with its development.8–12
However, the need to revisit this entity is evident: most
recent reports and case series on this topic are now over two
decades old. Are the typical cancer patients (those with lung
cancer, sarcoma, carmustine exposure, and radiation expo-
sure) still heavily represented, or should oncologists remain
vigilant for this rare entity in other settings as well? Do
cancer patients who develop a spontaneous pneumothorax
still commonly have metastatic cancer as the cause? Do
cancer patients who develop a spontaneous pneumothorax
still carry a poor prognosis of only a few months, even with
modern improvements in cancer care? These unanswered
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questions invite a modern day reexamination of the causes
and outcomes of spontaneous pneumothoraces in solid tumor
cancer patients.
PATIENTS AND METHODS
Identification of Patients
The study was approved by the Mayo Clinic Institu-
tional Review Board. Thereafter, the Mayo Clinic Patient
Registry in Rochester, Minnesota, identified all patients with
diagnoses of “spontaneous pneumothorax” and “cancer” be-
tween 1990 and 2004. Patients were not required to have an
active cancer to be included in this study; only a prior or
concurrent solid tumor cancer diagnosis was necessary. Pa-
tients with leukemia or hematologic malignancies were ex-
cluded, except for lymphoma patients. Patients with squa-
mous cell or basal cell carcinoma of the skin or with a
noninvasive malignancy were also excluded, given the low
likelihood of metastasis.
Review of Medical Records
One investigator (S.N.C.) reviewed all the medical
records, and select information was re-reviewed and con-
firmed by another investigator (A.J.). Spontaneous pneumo-
thorax is not well defined in the literature.13 Thus, for pur-
poses of this study, a spontaneous pneumothorax was defined
as a pneumothorax that was diagnosed in the absence of an
invasive procedure in the preceding 7 days. This 7-day
interval seemed conservatively appropriate, was derived from
the clinical experience of the investigative team, and was
thought unlikely to result in a traumatic pneumothorax as
being misconstrued as a spontaneous one. Patients who did
not meet this definition were not included.
The following information was retrieved and recorded
for each patient: (1) age at the time of the pneumothorax; (2)
cancer type; (3) cancer status (known active cancer or not);
(4) prior cancer therapy; (5) smoking history; (6) prior diag-
nosis of nonmalignant lung disease, such as chronic obstruc-
tive pulmonary disease; (7) recent radiographic testing with
results (recent chest radiographs were assumed to have been
completed); (8) method of management of the pneumothorax;
(9) number of days in the hospital; and (10) date of death or
last day of follow-up. Types of prior cancer therapy were
described by treatment modality and not further classified on
the basis of whether they targeted the thorax. This approach
was used because cancer treatments can have unforeseen
effects on the chest; for example, even abdominal surgery
might entail manipulation of the diaphragm and possibly
pneumothorax at a later date.14
In reviewing the medical record, only information that
was clearly documented was recorded on the data sheets. For
this reason, speculation as to whether the spontaneous pneu-
mothorax was primary or secondary or specifically caused by
the cancer is not included.
Statistical Analyses
Patient demographics are presented descriptively. Sur-
vival was defined as the interval from the date of diagnosis of
the spontaneous pneumothorax until the date of death. If the
latter was unknown, data were censored from the date of last
follow-up. Time intervals were rounded up to the nearest
month. JMP, Version 5.1 (SAS Institute, Inc., Cary, NC), was
used for statistical graphics. If a patient had had more than
one spontaneous pneumothorax, the date of diagnosis of the
first pneumothorax was used in summarizing the data.
Kaplan-Meier curves were constructed for all patients, with a
separate curve for patients with known active cancer at the
time of the spontaneous pneumothorax.
RESULTS
Overview
A total of 546 patients were identified with the assis-
tance of the Mayo Clinic Tumor Registry with a diagnosis of
spontaneous pneumothorax between 1990 and 2004. Exclud-
ing all noncancer patients, those without an antecedent, con-
current, or almost concurrent cancer diagnosis, and those who
did not meet the other criteria described earlier, yielded a
remaining 25 solid tumor cancer patients, approximately 5%
of the original group. This report focuses on these 25 patients.
Patient Demographics
The average age of the group at the time of develop-
ment of a spontaneous pneumothorax was 65 years (Table 1).
Twenty were men. Prior cancer therapy included radiation
(n  8), chemotherapy (n  5), surgery (n  19), and other
(n 2), such as hormonal therapy, with many patients having
received multiple treatment modalities for their cancer. Che-
motherapy consisted of paclitaxel, carboplatin, 5-fluorouracil,
cisplatin, etoposide, cyclophosphamide, procarbazine, and
carmustine. To our knowledge, only one patient had received
carmustine.
A variety of cancer types were represented, although
lung cancer and bladder cancer were the most common
(Table 2). Two patients, one with non-small cell lung cancer
and another with renal cell cancer, presented with a pneumo-
thorax within a few days of their cancer diagnoses. Thirteen
patients had known evidence of active cancer at the time of
TABLE 1. Baseline Characteristics*
Age, mean (SD) 65 (18)
Gender
Male
Female
205
Prior cancer therapy
Radiation
Chemotherapy
Surgery
Other
8
5
19
2
Smoker† 18
Nonmalignant lung disease
Chronic obstructive pulmonary disease
Hamartoma, resected
Tuberculosis
Lymphangioleiomyomatosis
Sleep apnea
Sarcoidosis
13
1
1
1
1
1
*Denotes numbers of patients unless otherwise specified. †Defined as having
smoked at least 1 year.
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diagnosis of the spontaneous pneumothorax. Of the 12 pa-
tients who did not have known active cancer, eight had been
diagnosed with cancer in the preceding 5 years.
Notably, the majority of patients within the group as a
whole were smokers, defined as the use of inhaled tobacco
products over the course of 1 year. As many as 18 patients, or
72% of the group, were deemed smokers. Thus, not surpris-
ingly, a sizable number of patients carried a history of chronic
obstructive pulmonary disease (n  13) and other non–
cancer-related lung disease (Table 1).
Management
Interestingly, a total of eight patients suffered more
than one episode of spontaneous pneumothorax. One patient
had as many as four successive episodes over a span of
roughly 8 years, and another patient had as many as three
over a span of roughly 5 months. Five of these patients had
underlying, noncancerous lung disease that appeared to be
responsible for these multiple events.
Management of this entity entailed notable morbidity.
Within the entire group, 22 events required a chest tube.
Within the entire group, 14 events required surgery that
entailed either a pleurodesis or a wedge resection of diseased
lung. A video-assisted thorascopic procedure accounted for
seven of these surgical procedures. A surgical approach or
pleurodesis occurred more often in patients with known
active cancer, with eight of 13 such patients requiring it.
Also, within the entire group, only two events required no
invasive procedure.
Similarly, the average number of days (SD) in the
hospital for each event that required hospitalization was 10
7. One patient was not hospitalized and therefore not included
in the calculation of average hospital stay. Only eight patients
underwent cancer restaging with a computed tomographic
scan of the chest within 7 days before or after the spontaneous
pneumothorax, although we cannot rule out the possibility
that patients might have had recent scans completed at an
outside facility.
Survival
The median survival for the group as a whole after a
first-time diagnosis of spontaneous pneumothorax was 31
months (Figure 1). Within the group with known active
cancer, the median survival was only 3 months, although
patients with more indolent tumors lived longer (Figure 2).
The median survival of the 12 patients with no active cancer
was 113 months. One patient died in the hospital while being
managed for a spontaneous pneumothorax.
DISCUSSION
The purpose of this study was to update our current
understanding of the causes and outcomes of spontaneous
pneumothoraces in solid tumor cancer patients. This entity
remains rare, accounting for less than 5% of all spontaneous
pneumothoraces. Lung cancer patients (20%) continue to be
overrepresented. Moreover, this study provides confirmatory
evidence that a spontaneous pneumothorax—specifically, in
patients with known active cancer—continues to be a serious
event associated with morbidity and a median survival of
only 3 months.
Updated observations are discussed below. First, 48%
of cancer patients in this study developed a spontaneous
pneumothorax in the absence of known active cancer. Many
were smokers and may well have had more than one reason
to explain their pneumothorax. Thus, continued vigilance for
this rare entity, particularly among smokers, who can suffer
great morbidity and mortality from this event as a result of
chronic obstructive pulmonary disease,15 should continue
even in patients who are thought to be cancer free. Second, in
patients without known active cancer, it is reasonable to treat
these patients aggressively. We define “aggressively” as us-
ing a multidisciplinary approach to determine the best, pos-
sibly invasive, approach for a given patient. It is true that only
a small fraction of patients in this study were restaged for
TABLE 2. Cancer Types
Cancer Type No. of Patients (n  25)*
Non-small cell lung 4
Bladder 4
Gynecologic 3
Prostate 3
Colorectal 2
Head and neck 2
Brain tumor 2
Renal cell 1
Sarcoma 1
Carcinoid 1
Melanoma 1
Esophageal 1
Breast 1
Hodgkin’s 1
Small cell lung 1
Hurthle cell 1
Unknown primary 1
*Does not add up to 25 because five patients had more than one cancer.
FIGURE 1. Median survival from the time of pneumothorax
was 31 months for the group as a whole.
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their cancer at the time of pneumothorax diagnosis. However,
the fact that many of these patients went on to live for many
months—even years—suggests that this entity should not be
assumed to be indicative of cancer recurrence, that cancer
restaging is not absolutely mandatory, and that there is clear
justification for treating this subgroup of patients aggressively
when this catastrophic event occurs.
Third, although the earlier literature points to specific
cancers (e.g., lung cancer and sarcoma) as predisposing
patients to the development of a spontaneous pneumothorax
and although it points to certain therapy (e.g., carmustine and
radiation) as putting patients at higher risk, the present series
shows that patients with a variety of malignancies under a
variety of clinical circumstances can develop this complica-
tion. In fact, only eight patients in this group had received
radiation, only five had lung cancer, only one had sarcoma,
and only one had received carmustine. Thus, the vigilance
suggested above should occur regardless of type of cancer or
type of prior therapy with perhaps a higher degree of watch-
fulness reserved for those patients with a smoking history.
It is important to point out that this study carries the
same limitations inherent in any retrospective study. Bias in
identifying cases can be exacerbated by inaccuracies of the
medical record diagnoses, by an overrepresentation of pa-
tients with certain cancers based on unique expertise within a
specific cancer center, and by referral patterns that often
funnel more complicated patients to tertiary care medical
centers. Moreover, gaps in information are inevitable. De-
spite such limitations, a relatively rare entity, such as spon-
taneous pneumothorax in solid tumor cancer patients, must
rely on a retrospective approach, and this approach remains
the only way to permit timely study completion.
CONCLUSIONS
This study provides updated information on the demo-
graphics and management of solid tumor cancer patients who
develop a spontaneous pneumothorax in an effort to allow
medi. As more contemporary studies begin to refocus on this
entity, the optimal method for counseling and managing
patients will be defined with greater clarity.
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FIGURE 2. When survival was examined only in patients
with active cancer, median survival was 3 months.
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